|
Delayed
Nasdaq
17:49:12 17/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.720 USD | +1.09% |
|
-4.62% | -10.58% |
Company Valuation: Galectin Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 122.8 | 67.15 | 102.7 | 80.96 | 268.2 | 371.1 | - |
| Change | - | -45.33% | 52.89% | -21.14% | 231.27% | 38.37% | - |
| Enterprise Value (EV) | 122.8 | 67.15 | 102.7 | 80.96 | 268.2 | 371.1 | 371.1 |
| Change | - | -45.33% | 52.89% | -21.14% | 231.27% | 38.37% | 0% |
| P/E | -3.98x | -1.74x | -2.24x | -1.7x | -8.67x | -12.3x | -16x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | -0.1x | -0.2x | -0.63x | 0.2x | 0.3x | 0.7x |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | -21.2x | -19.2x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -21.2x | -19.2x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.52 | -0.65 | -0.74 | -0.76 | -0.48 | -0.3 | -0.23 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | -17.5 | -19.3 |
| EBIT 1 | -30.18 | -38.35 | -38.07 | -42.43 | -20.08 | -17.5 | -19.3 |
| Net income 1 | -30.7 | -38.87 | -44.8 | -47.2 | -30.97 | -24.9 | -19.3 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 2.070 | 1.130 | 1.660 | 1.290 | 4.160 | 3.680 | 3.680 |
| Nbr of stocks (in thousands) | 59,341 | 59,426 | 61,849 | 62,762 | 64,473 | 100,850 | - |
| Announcement Date | 31/03/22 | 30/03/23 | 29/03/24 | 31/03/25 | 31/03/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -12.27x | - | - | - | 371M | |
| 31.46x | 5.67x | 16.98x | 1.03% | 45.91B | |
| 34.62x | 3.34x | 14.39x | -.--% | 44.25B | |
| -20.04x | 230.9x | -21.44x | -.--% | 41.99B | |
| 45.6x | 5.26x | 28.79x | -.--% | 39.58B | |
| 26.88x | 8.11x | 20.55x | 0.42% | 31.08B | |
| 35.05x | 5.75x | 26.13x | -.--% | 17.21B | |
| 24.9x | 2.15x | 9.33x | 1.07% | 14.96B | |
| 29.53x | 1.94x | 11.89x | -.--% | 13.42B | |
| Average | 21.75x | 32.89x | 13.33x | 0.32% | 27.64B | |
| Weighted average by Cap. | 24.69x | 43.16x | 12.25x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GALT Stock
- Valuation Galectin Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
